Sean Richardson discusses Alexion’s focus on rare and ultra-rare diseases, the level of support for these therapies from the UK government, awareness raising, diagnostics, and his future priorities.
Let’s please start this interview by introducing the UK affiliate of Alexion to our audience. How would you describe the scope of operations of the company in the country?
“We recently announced a partnership with Complement Pharmaceuticals to co-develop a complement inhibitor for neurodegenerative disorders, and our recent acquisition of Wilson Therapeutics fits perfectly within our metabolic portfolio. "
